Summary:
- Remedy Plan Therapeutics, a pharmaceutical company in Gaithersburg, MD, secured $18M in funding for developing new NAMPT inhibitors.
- The funding came from investors like Schooner Capital and Alexandria Venture Investments to support the advancement of RPT1G in treating AML and MDS.
- The company, led by CEO Greg Crimmins, focuses on developing NAMPT inhibitors that target diseases without causing harm to healthy tissues.
Article:
Remedy Plan Therapeutics Raises $18M in Funding for NAMPT Inhibitor Development
Remedy Plan Therapeutics, a clinical-stage pharmaceutical company based in Gaithersburg, MD, recently announced the successful completion of an $18 million funding round. This funding will support the company’s innovative approach to developing hyperbolic NAMPT inhibitors for various diseases.
Investors such as Schooner Capital and Alexandria Venture Investments showed confidence in Remedy Plan Therapeutics’ vision, joining other existing backers in this funding round. The company plans to utilize the funds to accelerate the development of RPT1G, a novel NAMPT inhibitor, through a Phase 1/2 trial targeting patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
Focus on Targeted Treatment
Under the leadership of CEO and Founder Greg Crimmins, Remedy Plan Therapeutics is dedicated to developing NAMPT inhibitors that specifically target diseased cells without causing harm to healthy tissues. This focus is crucial, as previous attempts to inhibit NAMPT activity have resulted in severe on-target toxicities in healthy cells, limiting their clinical effectiveness.
By utilizing an innovative approach that partially inhibits NAMPT activity, Remedy Plan Therapeutics aims to overcome this challenge and provide meaningful clinical benefits to patients across various disease areas, including oncology, autoimmunity, and metabolic disorders.
Overall, Remedy Plan Therapeutics’ commitment to advancing targeted treatments through NAMPT inhibitors represents a significant step forward in the field of pharmaceutical research and holds promise for improving patient outcomes in the future.
